期刊文献+

白色念珠菌的临床耐药性变迁及控制措施研究 被引量:3

The research of clinical resistance change and control measures of Candida albicans
下载PDF
导出
摘要 目的分析广西河池市第三人民医院2008~2011年白色念珠菌耐药性变化趋势,指导临床合理使用抗菌药物。方法回顾性调查该院2008年1月至2011年12月从临床分离的1 022株白色念珠菌,对8种常用抗真菌药物的耐药结果进行统计分析。结果该菌连续4年对两性霉素B的耐药率最低,为7.09%~8.80%,耐药率最高的为伊曲康唑,连续4年均大于80.00%。结论白色念珠菌对常用抗真菌药物都产生一定的耐药性,故应对送检标本及早进行真菌培养和药敏试验;为了减少多重耐药和深部真菌感染的发生,应合理使用抗菌药物和抗真菌药物。 Objective To analyse candida albicans resistance change trend for guiding clinical rational use of antimicrobiat agents from 200 to 2011Methods A retrospective survey in our hospital from January 2008 to Decem her 2011 from clinical 1022 strains separated candida albicans, drug resistances of 8 antibacterials were statistically analyaed. Results The bacteria for four consecutive years amphoteriein B in both the lowest rates were 7.09% -- 8.80 %. The highest drug resistance of this bacteria was lineaolid itraconazole, four consecutive annual average rates were more than 80.00 %. Conclusion Candida albicans antifungal can have resistance to common drugs commonly, so as to send the specimens fungi susceptibility test and training. In order to reduce multiple resistance and deep fungus infection occurrence, antibiotics and antifungal drugs should be used reasonably.
出处 《检验医学与临床》 CAS 2012年第23期2945-2946,共2页 Laboratory Medicine and Clinic
关键词 抗真菌药物 白色念珠菌 耐药性变迁 antifungal drugs candida albicans resistance change
  • 相关文献

参考文献8

二级参考文献9

共引文献30

同被引文献32

  • 1Akins RA. An update on antifungal targets and mechanisms of resis- tance in Candida albicans [J]. Med Mycol, 2005, 43(4): 285-318.
  • 2Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in AspergiUus fumigatus CYP51A based on protein homology modeling [J]. Antimierob Agents Che- mother, 2010, 54(6): 2425-2430.
  • 3Lamb DC, Kelly DE, White TC, et al. The R467K amino acid substi- tution in Candida albicaru sterol 14alpha-demethylase causes drug resistance through reduced afl-mity [J]. Autimicrob Agents Chemoth- er, 2000, 44(1): 63-67.
  • 4Chau AS, Mendrick CA, Sabatelli F J, et al. Application of real-time quantitative PCR to molecular analysis of Candida albican: strains exhibiting reduced susceptibility to azoles [J]. Antimicrob Agents Chemother, 2004, 48(6): 2124-2131.
  • 5Holmes AR, Keniya MV, Ivnitski-Steele I, et al. The monoamine ox- idase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and IvlFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates [J]. Antimierob Agents Chemother, 2012, 56(3): 1508-1515.
  • 6Vandeputte P, lscher F, Sanglard D, et al. In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization [J]. PLoS One, 2011, 6(10): e26962.
  • 7Johnston DA, Eberle KE, Sturtevant JE, et al. Role for endosomal and vacuolar GTPases in Candida albicans pathogenesis [J]. Infect Immun, 2009, 77(6): 2343-2355.
  • 8Oliver BG, Song JL, Choiniere JI-I, et al. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p [J]. Eukaryot Cell, 2007, 6(12): 2231-2239.
  • 9Hoot SJ, Smith AR, Brown RP, et al. An A643V amino acid substitu- tion in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans [J]. Antimicrob Agents Che- mother, 2011, 55(2): 940-942.
  • 10MacPherson S, Akache B, Weber S, et al, Candida albieans zinc cluster protein Upc2p confers resistance to antifungal drugs and isan activator of ergosterol biosynthetic genes [J]. Antimicrob Agents Chemother, 2005, 49(5): 1745-1752.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部